Azenosertib
- Generic Name
- Azenosertib
- Drug Type
- Small Molecule
- Chemical Formula
- C29H34N8O2
- CAS Number
- 2376146-48-2
- Unique Ingredient Identifier
- 9J13XU96Z1
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
- Conditions
- Uterine Serous CarcinomaUterine CarcinomaUterine Cancer
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Joyce Liu, MD
- Target Recruit Count
- 25
- Registration Number
- NCT06369155
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
- Conditions
- Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Gastroesophageal Junction AdenocarcinomaUnresectable Gastric CarcinomaUnresectable Gastroesophageal Junction AdenocarcinomaUnresectable Malignant Solid NeoplasmClinical Stage III Gastric Cancer AJCC v8Locally Advanced Gastroesophageal Junction AdenocarcinomaClinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Locally Advanced Gastric Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Biopsy ProcedureProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT06364410
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
- Conditions
- Breast Cancer FemaleBreast CancerHormone Receptor Negative Malignant Tumor Breast TripleHER2-negative Breast CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Filipa Lynce, MD
- Target Recruit Count
- 78
- Registration Number
- NCT06351332
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Target Recruit Count
- 44
- Registration Number
- NCT05743036
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Alliance for Multispecialty Research, LLC, Merriam, Kansas, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT05682170
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
- Conditions
- TumorsOvarian CancerBreast CancerLung CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05431582
A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
- Conditions
- Primary Peritoneal CarcinomaOvarian CancerPlatinum-resistant Ovarian CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Target Recruit Count
- 117
- Registration Number
- NCT05198804
- Locations
- 🇺🇸
Rutgers New Jersey Medical School, Newark, New Jersey, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Arizona Oncology Associates (Wilmot HOPE) - USOR, Tucson, Arizona, United States
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Conditions
- High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Target Recruit Count
- 170
- Registration Number
- NCT05128825
- Locations
- 🇺🇸
Site 0228 - Corewell Health Medical Group West, Grand Rapids, Michigan, United States
🇺🇸Site 0170-USA Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Site 0143 - HonorHealth, Phoenix, Arizona, United States
A Phase 1b Study of ZN-c3 in Chinese Subjects
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Zentera Therapeutics HK Limited
- Target Recruit Count
- 38
- Registration Number
- NCT04972422
- Locations
- 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China
🇨🇳Sichuan University Huaxi Hospital, Chengdu, Sichuan, China
🇨🇳Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Target Recruit Count
- 84
- Registration Number
- NCT04833582
- Locations
- 🇫🇷
Site 3604, Bordeaux, France
🇫🇷Site 3606, Paris, France
🇺🇸Site 0106, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.